Скачать с ютуб A Conversation with an MPN Specialist: ASH Updates в хорошем качестве

A Conversation with an MPN Specialist: ASH Updates

MPN Advocacy & Education International was joined by Dr. Andrew Kuykendall, Moffitt Cancer Center, to provide a brief update on what research was presented at ASH and answer patient questions. TIMESTAMPS 00:00 A Conversation with an MPN Specialist: ASH Updates 21:14 Can you explain the discrepancy between ET being a progressive disease and the fact that a person with ET can have a normal life expectancy? 25:16 Does ET always progress? 27:40 Regarding hydroxyurea, are the side effects dose-related and/or related to the length of time on hydroxyurea? 28:46 Does a low EPO value mean a greater likelihood of progression for ET? 30:24 Are there any new thoughts on triple negative ET? 31:19 Pegasys is often prescribed off-label for ET, so why can't BESREMi also be prescribed off-label and not wait for FDA approval? 33:34 Can you talk about CAR-T updates? 34:51 When is the MANIFEST-2 trial expected to end? 36:06 Can portal hypertension be the result of my ET? 37:32 Would oxygen on hand help with fatigue? 39:02 How many studies are consulting patients/consumers regarding desired patient-reported outcomes? 40:49 Were any updates presented on BESREMi investigating a more aggressive dosing strategy? 42:44 Am I more likely to progress with an ASXL1 and JAK2 mutations? 44:58 When is the best time to have a stem cell transplant? 48:17 Is progression to AML more likely with an MPL mutation? 48:38 Could following an anti-inflammatory diet help with my MPN? 50:40 Is there any benefit to using interferon to slow down the progression of the fibrosis of my MF? 51:22 Is there an estimated time when BESREMi will be approved for ET?